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Abstract
Background: Testosterone stimulates growth in many prostate tumours. The established GnRH analogue
leuprolide acetate is incorporated in a novel biodegradable polymer matrix (Atrigel
® delivery system), that can be
administered to reduce testosterone levels in men with advanced hormone-dependent prostate cancer. This novel
formulation is available as a 1-, 3- and most recently 6-month depot (Eligard
® 45 mg). The latter was shown to
lower and maintain safe and effective serum testosterone suppression in a clinical study.
Methods: A non-interventional study to confirm the efficacy and safety of 6-monthly leuprolide acetate (Eligard
®
45 mg) in routine urological practice was performed in Germany. Data were obtained from 1273 patients under
the care of 634 urologists, and were analysed descriptively. Concentrations of PSA and serum testosterone were
documented at the baseline visit and at 6 and 12 months following 6-monthly leuprolide acetate. The participating
physicians were also asked to assess the efficacy, tolerabilty and handling of 6-monthly leuprolide acetate.
Results: Serum concentrations of PSA and testosterone were decreased substantially within 6 months of initial
6-monthly leuprolide acetate administration. At 12 months, median reductions of 96% (to 0.5 ng/ml) in PSA, and
90% (to 8.9 ng/dl) in serum testosterone, were observed. Further PSA and serum testosterone decreases were also
observed in a subpopulation of patients who switched to 6-monthly leuprolide acetate from other GnRH
analogues. Physicians rated 6-monthly leuprolide acetate as easy to use, and patients reported good tolerability.
Adverse events occurred in 9% of patients; the majority were not serious. In particular, low rates of hot flushes
were reported.
Conclusions: This non-interventional study showed that the reliable reduction of PSA and testosterone levels
demonstrated in previous clinical studies of twice-yearly leuprolide acetate can also be achieved in routine clinical
practice. This study also confirmed good tolerability of 6-monthly leuprolide acetate in routine clinical use and
received positive appraisal from physicians.
Background
According to the Robert-Koch Institute (RKI) and the
Association of Population-based Cancer Registries in
Germany (GEKID), there are an estimated 60,000 new
cases of prostate cancer in Germany each year. Prostate
cancer is the most common malignancy in men, account-
ing for 25% of all new cases of cancer [1]. Testosterone
stimulates the growth of most prostate tumours.
Hormone deprivation therapy is therefore used to inhibit
further tumour growth, especially in patients with locally
advanced or metastatic prostate cancer. Androgen depri-
vation can be achieved either by surgical or medical cas-
tration (see the current German interdisciplinary
guideline for the early detection, diagnosis and therapy of
the various stages of prostate cancer, September 2009
[2]). A medical standard therapy is the injection of syn-
thetic analogues of gonadotropin-releasing hormone
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hormone, LHRH). These agents have a longer half-life
and a higher affinity to the pituitary GnRH-receptor than
physiological GnRH. After initial application of a GnRH-
analogue, serum testosterone levels increase transiently
over a period of one to two weeks. Testosterone inhibits
the release of GnRH and the pituitary gonadotropin
secretion via a negative feedback loop. Continuous
administration of a GnRH analogue inhibits the pulsatile
stimulation of gonadotropin secretion by physiological
GnRH, which eventually leads to reduced androgen pro-
duction. Within three weeks, most patients reach testos-
terone castration levels of < 20 ng/dL [3]. Leuprolide
acetate, which is the active ingredient of Eligard
® 45 mg
(Astellas Pharma GmbH), is one of the most commonly
used GnRH analogues.
Eligard
® (Astellas Pharma GmBH) is a new formulation
of leuprolide acetate, which combines the active ingredi-
ent with a biodegradable polymer matrix (Atrigel
® deliv-
ery system) to achieve sustained release of leuprolide
acetate. In Germany, the 1-month depot (Eligard
®
7.5 mg) was approved in December 2003 and the 3-
month depot (Eligard
® 22.5 mg) was approved in January
2004 for the treatment of advanced hormone-dependent
prostate cancer. The newest product, 6-monthly leupro-
lide acetate (Eligard
® 45 mg), was approved for the
German market in November 2006 and was launched in
March 2007. The liquid drug is injected subcutaneously
and forms a gel-like depot that slowly disintegrates and
continuously releases the active ingredient. A 12-month,
open-label, multicentre clinical trial [4] showed that in
patients with prostate cancer, 6-monthly leuprolide acet-
ate induced reliable and effective suppression of testos-
terone comparable to bilateral orchiectomy. Here we
report the results of a non-interventional study with
6-monthly leuprolide acetate. Based on a broad patient
population, this study investigated whether the efficacy
and safety findings of the clinical study could be con-
firmed in daily clinical practice in a large number of
patients (n = 1273). Experiences with the long dosing
interval were of special interest in this study.
Methods
The prospective, non-interventional study was performed
in accordance with the Arzneimittelgesetz § 67 section 6
[5]. A total of 634 urologists who had decided to treat
patients with advanced prostate cancer with 6-monthly
leuprolide acetate participated in this study. Diagnosis
and treatment decisions were at the sole discretion of the
treating physicians. During the study period, which lasted
from May 2007 to December 2008, study-related data
from 1273 patients were captured. The observational per-
iod for each patient was 12 months. Concentrations of
prostate-specific antigen (PSA) and serum testosterone
(optional) were documented at the baseline visit and
after 6 and 12 months. The physicians provided a global
assessment of therapy and collected data on the local tol-
erability of 6-monthly leuprolide acetate. Physicians also
reported on their experience of using the product and
the handling of the syringe. In addition, the occurrence
of adverse events was monitored and documented during
the entire observational period. Data were processed in
pseudonymised form and analysed descriptively.
The present study was conducted in accordance with
the Declaration of Helsinki, and was approved by the
Landesärztekammer Baden-Württemberg. All patients
provided written, informed consent.
Results and discussion
The mean age of the patients was 75 years. Further
demographic and medical characteristics of the patients
are summarised in Table 1. Approximately half of the
patients (48%) were treated with leuprolide acetate for
the first time. Of the remaining patients, one third were
pre-treated with a different monthly depot formulation
(either 1- month or 3- monthly) of the Astellas leupro-
lide acetate, and two thirds were pre-treated with other
GnRH analogues. The majority of patients received
Table 1 Characteristics of documented male patients with
advanced prostate cancer (total number = 1273)
Demographic data: mean (minimum, maximum)
Age (years) 75 (50, 97)
Weight (kg) 81 (45, 160)
Height (cm) 175 (157, 198)
Diagnosis/findings: mean
Time since first diagnosis (months) 33
Biopsy: Number of cores 8.2
Number of positive cores 4.5
cT1-2, % 44
cT3-4, % 32
M+, % 20
Gleason grade (1-5) 3.4
Gleason sum (2-10) 6.8
Therapy with GnRH analogues: number of patients (%)
First-time treatment 610 (48)
Pre-treatment* 652 (51)
3 monthly leuprolide acetate 210 (32.2)
Leuprolide acetate, Takeda Pharmaceutical 168 (25.8)
Goserelin acetate, AstraZenca 107 (16.4)
Buserelin acetate, Sanofi-Aventis 97 (14.9)
1 monthly leuprolide acetate 27 (4.1)
Leuprorelin acetate, Takeda Pharmaceutical 21 (3.2)
Other drugs 22 (3.4)
Missing data 15 (2.3)
*Percentage refers to patients with change of therapy (n = 652). Total n = 667
includes multiple namings: single n = 637; 2-fold: n = 15
Tunn BMC Urology 2011, 11:15
http://www.biomedcentral.com/1471-2490/11/15
Page 2 of 6GnRH analogue monotherapy, and 35.3% were given
additional treatment. In most cases the additional treat-
ment was anti-androgen therapy (78,9%, Table 2). A
punch biopsy had been performed in 95% of the patients
before the start of the study. The mean Gleason sum
(2-10) was 6.8. Premature discontinuation of therapy
was documented for 6% of the patients (n = 76). The
most common reasons for discontinuation were loss to
follow-up (26%, n = 20) and patient death during the
study (22%, n = 17).
Effective reduction of PSA and testosterone levels
Within the first six months, a 94% decrease in the med-
ian PSA value from 11.6 ng/mL to 0.7 ng/mL was
observed (Figure 1). PSA decreased further to a median
v a l u eo f0 . 5n g / m La tt h ee n do ft h eo b s e r v a t i o n a lp e r -
iod (corresponding to a 96% decrease). At this time
point, 50% of the patients had PSA values between 0.1
and 1.9 ng/mL (interquartile range). Measurement of
serum testosterone was optional. Testosterone concen-
trations were available for up to 350 patients, i.e. up to
29% of patients with PSA measurements, at each visit
(Figure 1). The median serum testosterone concentra-
tion decreased from 89 ng/dL to 10 ng/dL during the
first six months, and decreased further to 9 ng/dL at the
end of the observational period, corresponding to a 90%
decrease in serum testosterone.
PSA and testosterone concentrations were also analysed
in two subpopulations of patients who were pre-treated
with other GnRH analogues (patients with complete data
only). One of the subpopulations consisted of patients
who switched from leuprolide acetate, Takeda Pharmaceu-
tical (Trenantone
®) to 6-monthly leuprolide acetate
monotherapy (n = 99); the second subpopulation consisted
of patients who switched from goserelin acetate,
AstraZenca (Zoladex
®) to 6-monthly leuprolide acetate
monotherapy (n = 57). Within the first six months, a 93%
decrease in the median PSA value was observed in the
subpopulation that switched from leuprolide acetate,
Takeda Pharmaceutical to leuprolide acetate, Astellas
Pharma GmbH, from 5.8 ng/mL to 0.4 ng/mL. A 96.5%
decrease in the median PSA value from 8.6 ng/mL to 0.3
ng/mL was observed in the subpopulation that switched
from goserelin acetate to leuprolide acetate, Astellas
Pharma GmbH. The median serum testosterone levels
decreased from 150 ng/dL to 17.3 ng/dL during the first
six months in the leuprolide acetate, Astellas Pharma
GmbH subpopulation, corresponding to an 88% decrease.
The median serum testosterone levels decreased from 72.3
ng/dL to 18.0 ng/dL during the first six months in the
goserelin acetate subpopulation, and decreased further to
16.3 ng/dL at the end of the observational period, corre-
sponding to a 77% decrease. These data demonstrate an
effective reduction of PSA and testosterone levels by leu-
prolide acetate, Astellas Pharma GmbH in patients who
either received a GnRH analogue for the first time or were
switched from another GnRH analogue to leuprolide acet-
ate, Astellas Pharma GmbH.
Favourable therapy evaluation
The most frequent reason (90%) for prescribing
6-monthly leuprolide acetate, as given by the participat-
ing urologists, was the long dosing interval of the
6-months depot (Figure 2). Other common reasons
were the small injection volume (20%) and the short
needle of the pre-filled syringe (15%). A doctor’s assis-
tant prepared the syringe for more than half of the
patients (57%), whereas physicians prepared the syringe
in 42% of the cases (data was missing for 1% of
patients). Handling of the pre-filled syringe was regarded
as convenient or very convenient by the majority of
users (72%; Figure 2).
Good tolerability
The local tolerability of the product was assessed as good
or very good for most patients (92%) (Figure 2). Adverse
events (AEs) occurred in 108 (9%) of 1273 documented
patients (Table 3). Non-serious AEs were reported for 69
patients (5%) and serious adverse events (SAEs) were
documented in 39 patients (3%). No systematic allergic
reactions were reported for any patient. For 17 of 69
patients, a causal relationship between the occurrence of a
non-serious AE and the administration of 6-monthly leu-
prolide acetate was excluded, whereas 34 patients had AEs
which were assessed by the physicians as definitely related
to treatment. A causality assessment was missing or was
deemed not possible for 18 patients with non-serious AEs.
Most reported SAEs were tumour progression (i.e. metas-
tasis) or the requirement of surgical measures including
Table 2 Classification of patients receiving monotherapy
or combination therapy
Therapy Number of patients (%)
Monotherapy GnRH 724 (56.9)
Combination therapy 449 (35.3)
Bicalutamide 183 (40.8)*
Flutamide 171 (38.1)*
Zoledronic acid 59 (13.1)*
Cyproterone 57 (12.7)*
Oestramustine 12 (2.7)*
Docetaxel 6 (1.3)*
Missing data 10 (2.2)*
Total 498 (**)
Missing data 100 (7.9)
Total 1273 (100.0)
*Percentage refers to patients receiving a combination therapy (n = 449);
**Total includes multiple naming for combination therapy: Single: 405; 2-fold:
40; 3-fold: 3; 4-fold: 1
Tunn BMC Urology 2011, 11:15
http://www.biomedcentral.com/1471-2490/11/15
Page 3 of 6radical prostatectomy, surgery and hospitalisation. 25
patients (2%) died during the study. For 33 of 39 patients
with SAEs, a causal relationship between the SAE and
treatment with 6-monthly leuprolide acetate was excluded
or assessed as being unlikely. For one SAE (tumour pro-
gression with fatal outcome) in an 82-year-old patient, a
causal relationship to 6-monthly leuprolide acetate could
not be excluded. A causality assessment was missing for 5
patients with SAEs.
Comparison to previous experiences with 6-monthly
leuprolide acetate
In the above-mentioned clinical trial by Crawford and
colleagues [4], 6-monthly leuprolide acetate achieved a
97% decrease in PSA. At the end of the study (Month
12), the mean testosterone concentration of 103 patients
was 12.3 ng/dL (corresponding to 0.426 nmol/L), which
is well below the castration level. The present study is
the first non-interventional study performed since the
launch of 6-monthly leuprolide acetate in Germany in
2007. The results of the study show that under the condi-
tions of daily urological practice, PSA and testosterone
levels could be decreased to a similar extent as in the
clinical trial, confirming the therapeutic benefit of the 6-
month depot. In the current investigation, the non-
interventional study design provided a valuable tool,
despite its known methodological limitations, for the eva-
luation of the efficacy and tolerability of a new formula-
tion. This study was based on biochemical data that were
extrapolated to be an attribute of patient improvement,
which might not be realised for every patient in this non-
interventional study. An additional limitation could be
that interpretation of the data was influenced by approxi-
mately 50% of the patients who previously received
androgen blockade therapy. In contrast to clinical trials, a
larger and more heterogeneous group of patients could
be included, and a broader range of physicians could be
involved. Furthermore, this non-interventional study
allowed the collection of data that was not accounted for
in the Crawford clinical trial, such as data on the hand-
ling of the syringe and a global assessment of the therapy
by the physicians. With regard to the tolerability data,
the low incidence of documented hot flushes was notable.
Results from clinical trials show that the occurrence of
hot flushes is usually very common (> 1/10) [6]. A possi-
ble explanation for this discrepancy may be that many
physicians rate the occurrence of hot flushes not as an
AE, which needs to be documented, but rather as a ‘nor-
mal’ reaction under hormone deprivation, indicating the
effectiveness of the GnRH therapy.
-96%
-90%
Number of patients (Visit 1; 2; 3); PSA (1254; 1221; 1154), testosterone (231; 350; 300)
Figure 1 Median serum concentrations of PSA and testosterone during treatment with 6-monthly leuprolide acetate.
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The long dosing interval of 6-monthly leuprolide acetate
was the main reason given by the participating urolo-
gists for making the prescribing decision with regard to
the hormone deprivation therapy of their patients. In
particular, physicians felt that patients with stable dis-
ease, patients who like to travel, or who have difficulty
reaching a practice, may benefit from a longer interval
between two injections. The present non-interventional
study showed that the reliable reduction of PSA and
testosterone levels achieved by 6-monthly leuprolide
acetate injections twice a year, as demonstrated in the
clinical study, can also be achieved under the conditions
of daily urological practice. Furthermore, this study also
confirmed the good tolerability of 6-monthly leuprolide
acetate in routine clinical use.
Acknowledgements
We would like to thank the CRO MEDIDATA GmbH for processing the data.
Editorial support was provided by Darwin Healthcare Communications and
funded by Astellas Pharma GmbH.
Authors’ contributions
UWT takes full responsibility for the manuscript.
Conflicts of interests
UWT has received financial support for research projects and lectures from
Abbott, Astellas, Lilly, Novartis, Sanofi-Aventis, and Takeda.
Received: 21 April 2011 Accepted: 29 July 2011 Published: 29 July 2011
References
1. Cancer in Germany 2003-2004, Incidence and Trends. Robert-Koch
Institute; Association of Population-based Cancer Registries in Germany;
2008.
2. Wenz F, Martin T, Bahmer D, Martens S, Sedlmayer F, Wirth M, Miller K,
Heidenreich A, Schrader M, Hinkelbein W, et al: The German S3 Guideline
Prostate Cancer. Strahlentherapie und Onkologie 2010, 186:531-534.
*Percent of patients (n = 1273); Multiple namings were possible.
(%)
Reasons for prescribing 6-monthly leuprolideacetate*
Handling of pre-filled syringe*
Local tolerability*
Figure 2 Final assessment of 6-monthly leuprolide acetate therapy by the participating urologists. Legend. Diagnosis and treatment
decisions were at the sole discretion of the treating physicians. The physicians stated that the most frequent reasons for choosing 6-monthly
leuprolide acetate were the long dosage interval, small injection volume, and short cannula. Less frequent reasons for choosing 6-monthly
leuprolide acetate included compliance/patient’s request, costs, physician’s interest in 6-monthly leuprolide acetate, and good efficacy of the
Astellas leuprolide acetate. Other reasons were named in minor frequencies.
Table 3 The most common non-serious adverse events
Adverse event Number of patients (%)*
Local reaction at injection site: 41 (3.2)
Irritation 21 (1.6)
Nodule 7 (0.5)
Pain 5 (0.4)
Induration 3 (0.2)
Swelling 2 (0.2)
Burning sensation 2 (0.2)
Pruritus 1 (0.1)
Hot flushes 15 (1.2)
*Percentages are based on the total number of patients (n = 1273)
Tunn BMC Urology 2011, 11:15
http://www.biomedcentral.com/1471-2490/11/15
Page 5 of 63. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F:
EAU guidelines on prostate cancer. Eur Urol 2008, 53:68-80.
4. Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS: A 12-month
clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous
delivery system for leuprolide acetate for the treatment of prostate
cancer. J Urol 2006, 175:533-536.
5. § 67 Allgemeine Anzeigepflicht, section 6. Bekanntmachung der
Neufassung des Arzneimittelgesetzes. Bundesgesetzblatt 2005,
73:3394-3469.
6. Eligard 45 mg Summary of Product Characteristics. Astellas Pharma
GmbH. 2010.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2490/11/15/prepub
doi:10.1186/1471-2490-11-15
Cite this article as: Tunn: A 6-month depot formulation of leuprolide
acetate is safe and effective in daily clinical practice: a non-
interventional prospective study in 1273 patients. BMC Urology 2011
11:15.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tunn BMC Urology 2011, 11:15
http://www.biomedcentral.com/1471-2490/11/15
Page 6 of 6